Neuland Labs Q3 FY26: Revenue up 10% YoY, PAT down on base effect

Ebitda Margin CompressionResults View source PDF Explain this filing

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.2%Reaction day

₹13895.00

prior close

₹13000.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.5%-3.7% vs market

Pharmaceuticals peers, median of 159sector+0.4%-3.6% vs sector

On the reaction day the stock moved 3.7 pts less than Nifty Smallcap 250 and 3.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.5

10m

+5.4

15m

+5.4

30m

+4.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.2+0.5-3.7+0.4-3.6

Next day

-5.0+0.6-5.6+0.3-5.3

-6.8-0.1-6.7+0.0-6.8

-6.1-1.7-4.4-1.2-4.9

-4.3-1.8-2.5-1.7-2.6

-1.8-1.0-0.8-1.8-0.0

-6.3-1.7-4.6-2.5-3.8

15d

-8.5-6.3-2.2-6.9-1.5

-9.3-5.4-3.9-5.1-4.2

+7.6-3.2+10.8-3.5+11.1

+26.7+6.1+20.6+2.8+23.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q3 FY26 revenue rose 10.5% YoY to Rs 43,971 lakhs. 9M revenue up 8.6% to Rs 1,24,674 lakhs. Q3 PAT fell to Rs 4,057 lakhs vs Rs 10,159 lakhs YoY due to Rs 5,578 lakh one-time exceptional gain in Q3 FY25. 9M PAT Rs 15,133 lakhs vs Rs 23,230 lakhs. EBITDA margins compressed from about 23% to about 19% YoY on higher costs. Clean auditor review.

Likely market impact

Revenue growing but margins under pressure. PAT drop is mostly a prior-year base effect, not core weakness.